BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Stellar Biotechnologies, Inc. Presents Phase IIB Proposal to The U.S. National Science Foundation


7/7/2011 9:03:43 AM

PORT HUENEME, CA--(Marketwire - July 06, 2011) -

Stellar Biotechnologies, Inc. "Stellar" (TSX-V: KLH) (PINKSHEETS: SBOTF) is pleased to announce that its President, Frank Oakes and Executive VP, Corporate Development & Finance, Darrell Brookstein responded to an NSF invitation and presented Stellar's Phase IIB proposal (http://www.nsf.gov/eng/iip/sbir/phase_iib.jsp) for full implementation of commercial scale aquaculture systems for KLH (Keyhole Limpet Hemocyanin) production and development and deployment of a validated KLH-based immunogenicity assay to a committee of Program Directors of the National Science Foundation (NSF) at their Arlington, VA headquarters on June 30th.

The Phase IIB is a follow-up to Stellar's NSF grant under the prestigious TECP Program which was detailed in a December 14, 2010 press release -- http://stellarbiotechnologies.com/investors/news_releases/index.php?&content_id=56

Stellar is proposing a $500,000 grant and notice of an award, should one be granted, is expected later in 2011.

About The U.S. NSF (adapted from the NSF website; see http://www.nsf.gov/index.jsp)
-- The National Science Foundation is an independent federal agency created by Congress in 1950 "to promote the progress of science; to advance the national health, prosperity, and welfare; to secure the national defense..." With an annual budget of about $6.9 billion (FY 2010), they are the funding source for approximately 20 percent of all federally supported basic research conducted by America's colleges and universities. The NSF fulfills its mission chiefly by issuing limited-term grants - to fund specific research proposals that have been judged the most promising by a rigorous and objective merit-review system. Many of the discoveries and technological advances have been truly revolutionary. In the past few decades, NSF-funded researchers have won more than 180 Nobel Prizes as well as other honors too numerous to list.

About Stellar Biotechnologies, Inc. Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole LimpetHemocyanin). This evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source. Stellar Biotechnologies was founded to address the urgent need for sustained, commercial-scale supplies of high quality, GMP-grade KLH. Stellar has developed leading practices, facilities and proprietary capabilities to address this need.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Readers should not place undue reliance on such statements. Except in accordance with applicable securities laws, the Company expressly disclaims any obligation to update any forward-looking statements or forward-looking statements that are incorporated by reference herein. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of these releases.


Contact:

Darrell Brookstein
Executive VP, Corporate Development & Finance
dbrookstein@stellarbiotech.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES